A 10% weight loss in patients age 60 to 64 may be able to provide Medicare savings of $8 billion over 10 years and $35 billion over their lifetime, according to Kenneth E. Thorpe, PhD.
A 10% weight loss in patients age 60 to 64 may be able to provide Medicare savings of $8 billion over 10 years and $35 billion over their lifetime, according to Kenneth E. Thorpe, PhD. Thorpe is a professor and chair of health policy and management at the Emory Rollins School of Public Health. He also serves as executive director of the partnership to fight chronic diseases and as a consultant to biopharmaceutical company, VIVUS.
He says many of the government's current approaches to weight loss are not addressing obesity, which is responsible for the rising rates of diabetes, hypertension and dyslipdemia.
“Weight loss generates lower spending,” Thorpe says. “We spend 40% more on healthcare for obese people than for normal-weight people.”
He says if the Medicare program made evidence-based lifestyle modification programs-such as the YMCA’s Diabetes Prevention Program via UnitedHealthcare-available to everyone at age 60, it would generate $7 billion in savings over the next decade.
“The payers that don't have evidence-based workplace wellness programs are missing big opportunity,” he says. “We have a decade of data showing that it works.”
He is also hopeful about a range of investigational weight-loss drugs still pending FDA approval he says can help achieve a 10% to 15% reduction in weight.
Go back to the Managed Healthcare Executive eNews newsletter.
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
A Renewed Commitment to HIV Vaccine Development Despite Advancements in Antiretrovirals | AIDS 2024
July 25th 2024The HIV vaccine field has recently faced setbacks with trials like PrepVacc, Mosaico and Imbokodo ending early due to lack of preventive efficacy. Although there have been challenges, scientists have made discoveries showing that the immune system can be prepared to fight HIV with special antibodies.
Read More
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
ViiV Healthcare Will Not Continue Trials of Subcutaneous Cabenuva | AIDS 2024
July 25th 2024A substudy of the FLAIR phase 3 trial found that participants favored intramuscular injection of Cabenuva over the subcutaneous version due to pain and the development of nodules and reddening of the skin.
Read More